Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.
Publication
, Journal Article
George, DJ
Published in: Clin Adv Hematol Oncol
September 2017
Duke Scholars
Published In
Clin Adv Hematol Oncol
ISSN
1543-0790
Publication Date
September 2017
Volume
15
Issue
9
Start / End Page
690 / 694
Location
United States
Related Subject Headings
- Treatment Outcome
- Symptom Assessment
- Radium
- Prostatic Neoplasms, Castration-Resistant
- Patient Selection
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Metastasis
- Male
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
George, D. J. (2017). Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol, 15(9), 690–694.
George, Daniel J. “Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.” Clin Adv Hematol Oncol 15, no. 9 (September 2017): 690–94.
George DJ. Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2017 Sep;15(9):690–4.
George, Daniel J. “Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer.” Clin Adv Hematol Oncol, vol. 15, no. 9, Sept. 2017, pp. 690–94.
George DJ. Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2017 Sep;15(9):690–694.
Published In
Clin Adv Hematol Oncol
ISSN
1543-0790
Publication Date
September 2017
Volume
15
Issue
9
Start / End Page
690 / 694
Location
United States
Related Subject Headings
- Treatment Outcome
- Symptom Assessment
- Radium
- Prostatic Neoplasms, Castration-Resistant
- Patient Selection
- Oncology & Carcinogenesis
- Neoplasm Staging
- Neoplasm Metastasis
- Male
- Humans